Relay Therapeutics (RLAY) is a clinical-stage precision medicines company focused on targeted oncology, with a $4.4 billion market cap. RLAY has surged 486% over the past year. Shares are trading near a new 3-year high.
Technical momentum is strong, but fundamentals show that revenue is expected to decrease by more than 30% this year. Valued at $4.4 billion, Relay Therapeutics (RLAY) is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology.
I found today's Chart of the Day by using Barchart's powerful screening functions to sort for stocks with the highest technical buy signals and superior current momentum. I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. The Trend Seeker issued a new "Buy" signal on June 2.
Since then, the stock has gained 27.32%. A $20 Billion Reason Why Intel Stock Is in Focus Marvell Technology (MRVL) Stock Might Offer a Quick Bounce Before Earnings Most Analysts Still Aren't Bullish on Tesla Stock, Even After Recent Selloff. Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox.
Editor's Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.
Relay Therapeutics scored a 3-year high of $20.79 on July 9. Relay Therapeutics has a Weighted Alpha of 383.66. RLAY has a 100% "Buy" opinion from Barchart.
Extract — continue reading at the source.
